Marco Q.
- Country
- Italy
- Department
- Nefrologia e dialisi
Research Overview
Data & Insights
Has run more than one trial at 15 of 261 partner sites.
Specializations
Haematological malignancies
Marco Quaglia’s clinical research activity is centred on non-Hodgkin lymphoma, with strong involvement in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and peripheral T-cell lymphoma. His trial portfolio also extends to Hodgkin lymphoma, marginal zone lymphoma, and aggressive B-cell subtypes requiring novel therapeutic strategies.
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Chronic lymphocytic leukemia
- Peripheral T-cell lymphoma
The research landscape includes interest in targeted therapies, immunotherapy, and treatment approaches for relapsed or refractory lymphoid disease.
Myeloid disorders and myeloproliferative neoplasms
His studies cover acute myeloid leukemia, chronic myeloid leukemia, myelofibrosis, polycythemia vera, and essential thrombocythemia. This area also includes myelodysplastic syndromes and related myeloproliferative neoplasms, reflecting a focus on disorders with complex risk profiles and unmet therapeutic needs.
- Acute myeloid leukemia
- Myelofibrosis
- Polycythemia vera
- Essential thrombocythemia
His involvement spans JAK-inhibitor-related disease settings, transplant-related care, and emerging approaches for FLT3-mutated AML and other high-risk haemato-oncologic conditions.
Gastrointestinal and immune-mediated disease
Marco Quaglia is also involved in trials for ulcerative colitis, Crohn’s disease, and inflammatory bowel disease more broadly, alongside studies in Clostridioides difficile infection and recurrent respiratory infection prevention. This area highlights a therapeutic interest in chronic inflammatory and immune-mediated conditions.
- Ulcerative colitis
- Crohn’s disease
- Clostridioides difficile infection
- Recurrent lower respiratory tract infections
His research activity in this field reflects attention to mucosal inflammation, infection-related complications, and long-term disease control.
Solid tumours and thoracic oncology
His clinical trial involvement includes non-small cell lung cancer, small cell lung cancer, pleural mesothelioma, breast cancer, ovarian cancer, gastric cancer, and metastatic colorectal cancer. The scope also extends to melanoma and selected advanced solid tumours with difficult-to-treat biology.
- Non-small cell lung cancer
- Pleural mesothelioma
- Breast cancer
- Ovarian cancer
These studies align with therapeutic interest in precision oncology, antibody-based treatments, and treatment-resistant solid malignancies.
Cardiovascular, renal, and supportive care medicine
Marco Quaglia’s portfolio also includes acute myocardial infarction, acute coronary syndrome, heart failure prevention, acute kidney injury, chronic kidney disease, and mechanical valve anticoagulation. Additional involvement covers idiopathic pulmonary fibrosis, gout with hyperuricemia, and major depression, showing a broader interest in supportive and comorbidity-focused medicine.
- Acute myocardial infarction
- Chronic kidney disease
- Mechanical valve anticoagulation
- Idiopathic pulmonary fibrosis
His research activity in this domain includes cardiovascular risk reduction, renal protection, and management of complex medical conditions in hospital-based care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.